Repare Therapeutics
RPTX
RPTX was delisted on the 27th of January, 2026.
78 hedge funds and large institutions have $379M invested in Repare Therapeutics in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 25 reducing their positions, and 7 closing their positions.
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
16% more capital invested
Capital invested by funds: $327M → $379M (+$52.5M)
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
6.19% more ownership
Funds ownership: 78.91% → 85.1% (+6.2%)
1% more funds holding
Funds holding: 77 → 78 (+1)
8% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 25
35% less call options, than puts
Call options by funds: $87K | Put options by funds: $133K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
+$27.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.55M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.11M |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$1.92M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.1M |
| 2 |
SCM
Sio Capital Management
New York
|
-$1.57M |
| 3 |
BlackRock
New York
|
-$1.33M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$1.13M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$1.08M |
RPTX Hedge Fund Activity: Q2 2023 in Review
78 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q2 2023, worth a combined $379M — up 16% from $327M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new RPTX positions and 7 closed out — a net gain of 1 holder — while 23 added to existing stakes and 25 trimmed.
The largest buyer was Versant Venture Management, opening a new position worth an estimated $27.3M. The largest seller was Millennium Management, cutting an estimated $3.1M.
- 78 institutional investors held Repare Therapeutics (RPTX) as of Q2 2023, up from 77 in Q1 2023.
- Funds reported $379M of Repare Therapeutics stock for Q2 2023, up 16% quarter-over-quarter.
- 8 funds opened new Repare Therapeutics positions in Q2 2023 and 7 closed out, a net change of +1 holder.
- The largest Repare Therapeutics buyer in Q2 2023 was Versant Venture Management, an estimated $27.3M added.
- The largest Repare Therapeutics seller in Q2 2023 was Millennium Management, an estimated $3.1M sold.
Based on aggregated 13F filings for Q2 2023.